Figure 1.

FG-2216 increases plasma-EPO levels in healthy controls and in HD patients with and without remaining renal tissue. Twenty-four-hour kinetics of plasma EPO levels after a single dose of FG-2216. (A through C) Individual values are depicted for control subjects (A), nephric HD patients (B), and anephric HD patients (C). All individuals except one received FG-2216 at a dosage of 20 mg/kg; patient 4 in the anephric group (blue line in C) was accidentally underdosed with approximately 4 mg/kg.